Answers are grounded in this paper and cite their sources.
Ancillary trial analysis reveals circulating dipeptidyl peptidase 3 predicts mortality and organ support in cardiogenic shock, highlighting its value for risk stratification.
Cardiogenic shock (CS) is burdened with high mortality. Efforts to improve outcome are hampered by the difficulty of individual risk stratification and the lack of targetable pathways. Previous studies demonstrated that elevated circulating dipeptidyl peptidase 3 (cDPP3) is an early predictor of short-term outcome in CS, mostly of ischemic origin. Our objective was to investigate the association between cDPP3 and short-term outcomes in a diverse population of patients with CS.
No takes yet. Share an insight, caveat, or question.
Picod et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: